Displaying drugs 10976 - 11000 of 12697 in total
Linifanib
Linifanib (ABT-869) is a small molecule vascular endothelial growth factor (VEGF) receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of new blood vessels that supply the tumor with oxygen and nutrients and by inhibiting key angiogenic signaling pathways. Linifanib is intended for the treatment...
Investigational
Matched Description: … Linifanib is intended for the treatment of hematologic malignancies and the solid tumors. ... receptor-based kinase inhibitor that is designed to suppress tumor growth by preventing the formation of …
1alpha,24S-Dihydroxyvitamin D2
LR-103 is a naturally occurring D-hormone that is produced by the kidneys from vitamin D. LR-103 is one of the D-hormones produced from Hectorol. It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease (CKD). Studies have shown LR-103 has the same potency as calcitriol,...
Investigational
Matched Description: … LR-103 is one of the D-hormones produced from Hectorol. ... It is developed for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease …
Poloxamer 407
Poloxamer 407 is a polyoxyethylene polymer and hydrophilic non-ionic surfactant. It consists of a central hydrophobic block of polypropylene glycol that is flanked on each side by polyethylene glycol blocks, both hydrophilic in nature. Poloxamer 407 is used as an emulsifying agent and solubilizing agent in cosmetic and personal products...
Investigational
Matched Description: … It consists of a central hydrophobic block of polypropylene glycol that is flanked on each side by polyethylene …
BB-301
BB-301 is a modified AAV serotype 9 (AAV9) capsid expressing a unique, single bifunctional construct promoting co-expression of both codon-optimized Poly-A Binding Protein Nuclear-1 (PABPN1) and two small inhibitory RNAs (siRNAs) against mutant PABPN1. Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).
Investigational
Matched Description: … serotype 9 (AAV9) capsid expressing a unique, single bifunctional construct promoting co-expression of ... [A260112] Developed by Benitec Biopharma, BB-301 is being investigated for the treatment of Oculopharyngeal …
Tesevatinib
Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases, Esophageal Cancer, and Leptomeningeal Metastases, among others.
Tesevatinib is a potent inhibitor of multiple RTKs implicated in driving tumor cell proliferation and tumor vascularization (blood vessel formation). Tesevatinib inhibits the EGF, HER2, and VEGF RTKs,...
Investigational
Matched Description: … Tesevatinib inhibits the EGF, HER2, and VEGF RTKs, each of which is a target of currently approved cancer ... demonstrated potent inhibition of tumor growth and causes tumor regression. ... Tesevatinib has been used in trials studying the treatment of Cancer, Stomach Cancer, Brain Metastases …
αAβ–Gas6
αAβ–Gas6 is a chimeric fusion protein being investigated in preclinical studies as an immunotherapeutic agent for Alzheimer's disease (AD). It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is...
Experimental
Matched Description: … It is made of a single chain variable fragment (scFv) of an Amyloid β (Aβ)-targeting monoclonal antibody ... [A253203,A253208] αAβ–Gas6 is a phagocyte inducer of Aβ,[A253203] which is the main component of the ... fused with a truncated receptor binding domain of growth arrest-specific 6 (Gas6), which is a ligand …
4-Methyl-2,5-dimethoxyamphetamine
A psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of action may be similar to those of LSD.
Experimental
Illicit
Matched Description: … action may be similar to those of LSD. ... psychedelic phenyl isopropylamine derivative, commonly called DOM, whose mood-altering effects and mechanism of …
Endostar
Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. Endostar has been investigated for the treatment of Non-small Cell Lung Cancer.
Investigational
Matched Description: … Endostar is under investigation for the treatment of Nasopharyngeal Carcinoma. ... Endostar has been investigated for the treatment of Non-small Cell Lung Cancer. …
Opicinumab
Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses of BIIB033 in Healthy Japanese Participants).
Investigational
Matched Description: … Single and Multiple Doses of BIIB033 in Healthy Japanese Participants). ... Opicinumab is under investigation in clinical trial NCT02641041 (Safety, Tolerability, and Pharmacokinetics of …
ARC-19499
ARC-19499 is under investigation in clinical trial NCT01191372 (First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients).
Investigational
Matched Description: … Study of ARC19499 Administered to Hemophilia Patients). ... ARC-19499 is under investigation in clinical trial NCT01191372 (First-in-Human and Proof-of-Mechanism …
Rimtuzalcap
Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under investigation for the treatment of essential tremor.
Investigational
Matched Description: … investigation for the treatment of essential tremor. ... Rimtuzalcap is a novel modulator of small-conductance calcium-activated potassium channels that is under …
Udifitimod
Udifitimod is under investigation in clinical trial NCT05014438 (A Study of BMS-986166 or Branebrutinib for the Treatment of Participants With Atopic Dermatitis).
Investigational
Matched Description: … for the Treatment of Participants With Atopic Dermatitis). ... Udifitimod is under investigation in clinical trial NCT05014438 (A Study of BMS-986166 or Branebrutinib …
MB07811
MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. MB07811 combines a novel thyroid hormone receptor agonist with the...
Investigational
Matched Description: … MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower ... The combination of selectivity for the beta form of the receptor, liver targeting and other structural ... is designed to provide significant efficacy while avoiding side effects associated with activation of …
Tunicamycin
Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P HexNAc-1-P family of enzymes. One member of this family is the enzyme GlcNAc phosphotransferase (GPT), which catalyzes the transfer of N-acetylglucosamine-1-phosphate from UDP-N-acetylglucosamine to dolichol phosphate in the first step of glycoprotein synthesis in eukaryotes. Tunicamycin blocks...
Experimental
Matched Description: … HexNAc-1-P family of enzymes. ... of glycoprotein synthesis in eukaryotes. ... Tunicamycin is a mixture of homologous nucleoside antibiotics that inhibits the UDP-HexNAc: polyprenol-P …
DG041
DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of arterial thrombosis and its complications.
DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor for prostaglandins E2. EP3 is a target that associates with increased risk of various vascular...
Investigational
Matched Description: … EP3 is a target that associates with increased risk of various vascular diseases. ... DG041 is a novel, first-in-class, orally-administered small molecule developmented for the prevention of ... DG041, an anti-platelet compound, has shown to be a selective and potent antagonist of the EP3 receptor …
ILY101
ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of phosphate anions from the gastrointestinal tract. ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works by reducing the systemic absorption of dietary phosphate. ILY101 is designed to allow...
Investigational
Matched Description: … by reducing the systemic absorption of dietary phosphate. ... ILY101 is a metal-free, non-absorbed polymeric drug designed for the selective binding and removal of ... ILY101 is being developed for the treatment of hyperphosphatemia in CKD patients on dialysis and works …
LCP-AtorFen
LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect. LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol levels, addressing three...
Investigational
Matched Description: … atorvastatin (the active ingredient of Lipitor®) and the lowest dose of fenofibrate without food effect ... LCP-AtorFen is a fixed-dose combination therapy for the treatment of high cholesterol levels combining ... LCP-AtorFen is designed to be a once daily tablet offering a powerful and safe treatment of high cholesterol …
Taberminogene vadenovec
Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based medicine, being developed to prevent the blocking of veins and arteries that frequently occurs after vascular surgery. The initial target market is haemodialysis graft access surgery, a procedure in which patients whose kidneys have...
Investigational
Matched Description: … Taberminogene vadenovec (EG004) is a novel product consisting of a local delivery device and a gene-based ... medicine, being developed to prevent the blocking of veins and arteries that frequently occurs after ... EG004 has completed a Phase II trial, this being the first part of the Phase II/III study for which it …
VPM4001
VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete interferon-γ and interleukin-2 (LNCaP/IL-2/IFN-γ). Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells.
Investigational
Matched Description: … VPM4001 is an allogeneic vaccine for treatment of prostate carcinoma. ... Interferon-γ enhances presentation of tumour antigens, whereas interleukin-2 stimulates T cells. ... It consists of irradiated human LNCaP cells that have been genetically modified to permanently secrete …
AT1391
AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients with diabetes.
Investigational
Matched Description: … AT1391 is a daily insulin skin patch designed to provide continuous basal levels of insulin for patients …
Hexoprenaline
Hexoprenaline is a stimulant of beta 2 adrenergic receptors. It is used as a bronchodilator, antiasthmatic, and tocolytic agent.
Experimental
Withdrawn
Matched Description: … Hexoprenaline is a stimulant of beta 2 adrenergic receptors. …
Fulranumab
Fulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and Arthralgia, among others.
Investigational
Matched Description: … Fulranumab has been used in trials studying the treatment of Pain, Cystitis, Neuralgia, Joint Pain, and …
Eltanolone
Eltanolone is under investigation in clinical trial NCT02603926 (Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone).
Investigational
Matched Description: … Eltanolone is under investigation in clinical trial NCT02603926 (Treatment of Fragile-X Associated Tremor …
Dulanermin
Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma, and Metastatic Colorectal Cancer.
Investigational
Matched Description: … Dulanermin has been used in trials studying the treatment of Colorectal Cancer, Non-Hodgkin's Lymphoma …
Navicixizumab
Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Investigational
Matched Description: … Navicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab …
Displaying drugs 10976 - 11000 of 12697 in total